The Association for Accessible Medicines’ report on Medicare Part D tiering revealed low coverage rates for insulin and adalimumab biosimilars across plans.
Despite the US having more biosimilar options than ever before, Medicare Part D plans still prefer reference insulin glargine (Lantus) and adalimumab (Humira) over lower-priced biosimilar alternatives, according to a report from the Association for Accessible Medicines (AAM).
The report looked at results from Avalere’s analysis on understanding the distribution of biosimilars relative to their originators on Medicare Part D formulary tiers for program year (PY) 2023. Avalere synthesized public use files (PUFs) from PY 2024 to assess coverage, tiering, and utilization management of drugs covered under Part D plans, including Medicare Advantage plans, focusing specifically on the insulin glargine, adalimumab, epoetin alfa, pegfilgrastim, and filgrastim markets.
Avalere included over 5500 plans across all 50 states and Washington, DC, and the 5 largest Part D parent organizations in 2023 (United Healthcare, Humana, CVS, Centene, Cigna), regardless of whether they covered any of the studied products.
By parent organization, the researchers looked at:
Results showed that Lantus generally had higher coverage, preferred tiering, and less restrictive utilization management (UM) compared with its biosimilars. While 80% of plans covered branded or unbranded Lantus, less than 10% of plans covered branded or unbranded insulin biosimilars. There were also no differences in coverage for prefilled pens vs prefilled syringes for coverage, tiering, or UM. United Healthcare, CVS, Centene, and Cigna did not cover any insulin biosimilars.
Similarly, immunological agent biosimilars were significantly less likely to be covered by plans compared with their reference products. When covered, immunological agent biosimilars were typically placed on specialty tiers, indicating a higher level of restriction or management compared with reference products.
Humira biosimilars were not covered, and prior authorization was required for Humira, suggesting that plans were more inclined to cover the reference product rather than its biosimilars. UM strategies like prior authorization were commonly applied to control access to Humira. However, CVS, Cigna, and Centene did not cover any adalimumab biosimilars despite 8 products entering the market by the end of July 2023.
Although some biosimilars, such as Cyltezo, were covered by a higher number of plans compared with other Humira biosimilars, overall coverage of Humira biosimilars remained low across all plans, likely because it was the first adalimumab biosimilar to be granted interchangeability status.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.